Guerra Pan Advisors LLC Purchases 87 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Guerra Pan Advisors LLC increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 10.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 897 shares of the medical equipment provider’s stock after buying an additional 87 shares during the quarter. Guerra Pan Advisors LLC’s holdings in Intuitive Surgical were worth $303,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. DGS Capital Management LLC grew its position in Intuitive Surgical by 20.8% during the fourth quarter. DGS Capital Management LLC now owns 867 shares of the medical equipment provider’s stock worth $292,000 after buying an additional 149 shares in the last quarter. Keel Point LLC boosted its holdings in shares of Intuitive Surgical by 3.6% in the 4th quarter. Keel Point LLC now owns 1,258 shares of the medical equipment provider’s stock worth $424,000 after purchasing an additional 44 shares in the last quarter. Sentry Investment Management LLC boosted its holdings in shares of Intuitive Surgical by 62.0% in the 4th quarter. Sentry Investment Management LLC now owns 3,303 shares of the medical equipment provider’s stock worth $1,114,000 after purchasing an additional 1,264 shares in the last quarter. Mackenzie Financial Corp boosted its holdings in shares of Intuitive Surgical by 15.7% in the 4th quarter. Mackenzie Financial Corp now owns 289,405 shares of the medical equipment provider’s stock worth $97,634,000 after purchasing an additional 39,238 shares in the last quarter. Finally, Strs Ohio boosted its holdings in shares of Intuitive Surgical by 9.3% in the 4th quarter. Strs Ohio now owns 178,655 shares of the medical equipment provider’s stock worth $60,271,000 after purchasing an additional 15,233 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on ISRG shares. Royal Bank of Canada upped their price objective on Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a report on Wednesday, January 24th. Truist Financial upped their price objective on Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 24th. Stifel Nicolaus upped their price objective on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Piper Sandler upped their price objective on Intuitive Surgical from $325.00 to $425.00 and gave the stock an “overweight” rating in a report on Wednesday, January 24th. Finally, Wells Fargo & Company upped their price objective on Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a report on Friday, January 19th. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average price target of $375.70.

Intuitive Surgical Price Performance

NASDAQ:ISRG traded up $5.09 during mid-day trading on Tuesday, hitting $382.45. The company’s stock had a trading volume of 638,201 shares, compared to its average volume of 1,622,066. The business’s fifty day moving average is $388.13 and its two-hundred day moving average is $341.56. The stock has a market cap of $135.56 billion, a price-to-earnings ratio of 75.03, a PEG ratio of 5.97 and a beta of 1.36. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Tuesday, January 23rd. The medical equipment provider reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.48 by $0.12. Intuitive Surgical had a net margin of 25.24% and a return on equity of 13.11%. The company had revenue of $1.93 billion during the quarter, compared to the consensus estimate of $1.89 billion. During the same quarter in the prior year, the firm earned $0.91 EPS. Intuitive Surgical’s quarterly revenue was up 16.6% on a year-over-year basis. Analysts anticipate that Intuitive Surgical, Inc. will post 4.93 EPS for the current fiscal year.

Insider Activity

In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of the firm’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the transaction, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at approximately $736,800. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the transaction, the vice president now owns 26,877 shares of the company’s stock, valued at $10,349,795.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Mark Brosius sold 196 shares of the firm’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the transaction, the senior vice president now directly owns 1,842 shares in the company, valued at approximately $736,800. The disclosure for this sale can be found here. In the last three months, insiders have sold 248,418 shares of company stock worth $95,927,097. 0.80% of the stock is currently owned by corporate insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.